Jason Imbriglio, Ph.D.

Vice President, Head of Platform Technology

Jason Imbriglio Portrait

Jason brings more than 16 years of drug discovery and medicinal chemistry expertise to Roivant Discovery.

Prior to joining Roivant, Jason was a recognized leader in Merck’s global discovery chemistry department where he held positions of increasing responsibility, most recently as director of chemical biology, leading teams across all levels of preclinical discovery including target identification, target validation, lead identification and lead optimization. Jason was a founding member of Merck’s chemical biology group and a co-lead of Merck’s targeted protein degradation group. Jason contributed to the discovery of five development candidates, three INDs and was a co-inventor in the discovery of the beta-lactamase inhibitor Relebactam.

Jason has authored over 30 peer-reviewed journal articles and holds 12 patents spanning a diverse set of therapeutic areas. He holds a bachelor of arts degree in biology and bachelor of science degree in chemistry from the University of Massachusetts in Amherst, Mass. where he was a recognized Howard Hughes Undergraduate Research Fellow, a doctor of philosophy degree in organic chemistry from the University of Arizona in Tucson, Az. and a National Institute of Health Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship at Boston College in Chestnut Hill, Mass.                                                          

Follow Jason: